---
title: "Rein Therapeutics delays 10-K, expects $37.0 million impairment on LTI-01"
url: "https://aibio.space/news/rein-therapeutics-delays-10-k-expects-37-0-million-impairment-lti-01/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-03-31"
section: "Distress"
tickers: "NASDAQ:RNTX"
source: "https://www.sec.gov/Archives/edgar/data/1420565/000119312525068896/d930653dnt10k.htm"
summary: "The impairment follows a temporary delay of further clinical work on LTI-01. The company, formerly Aileron Therapeutics, needs more time to finish its impa"
---

By the aibio.space news desk.

Sources

- [Rein Therapeutics, Inc. NT 10-K (2025-03-31)](https://www.sec.gov/Archives/edgar/data/1420565/000119312525068896/d930653dnt10k.htm)

[RNTX](https://aibio.space/companies/rein-therapeutics/)

2025-03-31

# Rein Therapeutics delays 10-K, expects $37.0 million impairment on LTI-01

Tickers [RNTX](https://aibio.space/companies/rein-therapeutics/)

The impairment follows a temporary delay of further clinical work on LTI-01. The company, formerly Aileron Therapeutics, needs more time to finish its impairment assessment.

## Key facts

- **Company**: Rein Therapeutics, Inc. (NASDAQ: RNTX)

- **News type**: Distress

- **Primary source**: [Rein Therapeutics, Inc. NT 10-K (2025-03-31)](https://www.sec.gov/Archives/edgar/data/1420565/000119312525068896/d930653dnt10k.htm)

*A stone federal courthouse. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.*

Rein Therapeutics, Inc. (Nasdaq: [RNTX](https://aibio.space/companies/rein-therapeutics/)), formerly Aileron Therapeutics, Inc., said it cannot file its annual report on Form 10-K for the fiscal year ended December 31, 2024 on time without unreasonable effort or expense.

In a [late filing notice dated March 31, 2025](https://www.sec.gov/Archives/edgar/data/1420565/000119312525068896/d930653dnt10k.htm), the Austin, Texas company said it needs more time to complete certain processes. Those include finishing its assessment of impairment losses on intangible assets for 2024.

Rein expects its 2024 results to include an impairment loss on intangible assets of approximately $37.0 million. An impairment is a write-down that cuts the value an asset carries on the balance sheet. The company said the charge is tied to the temporary delay of further clinical development of LTI-01, its product candidate for patients with loculated pleural effusion.

The company said it did not incur an impairment loss on intangible assets during the year ended December 31, 2023.

Rein said it has filed all other periodic reports required during the preceding 12 months.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

RNTX

Rein Therapeutics, Inc.

NASDAQ · United States

Open the starter desk

## More in Distress

Distress

### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/)

Oct 29, 2026

Distress

### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/)

Oct 29, 2026

Distress

### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/)

Oct 28, 2026

---
Source page: https://aibio.space/news/rein-therapeutics-delays-10-k-expects-37-0-million-impairment-lti-01/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Rein Therapeutics delays 10-K, expects $37.0 million impairment on LTI-01", 2025-03-31, https://aibio.space/news/rein-therapeutics-delays-10-k-expects-37-0-million-impairment-lti-01/